[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359369-105":59,"doc-detail-359369-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","research-progress-of-nanodelivery-platforms-in-the-diagnosis-and-treatment-of-esophageal-cancer","Research Progress of Nanodelivery Platforms in the Diagnosis and Treatment of Esophageal Cancer","","Esophageal cancer therapy is constrained by radiotherapy and chemotherapy toxicity, multidrug resistance, and limited immune responsiveness. Nanotechnology provides precision targeting and motivates major platform innovations. The review details advances including improved efficacy with reduced toxicity, strategies to reverse drug resistance, photodynamic/gene/immunotherapy co-delivery to remodel the tumor microenvironment and activate “cold tumors”, and visualized integrated diagnostic-therapeutic platforms. Remaining barriers in biological penetration and mass manufacturing require biomimetic, intelligent, green production and organoid screening to bridge translation and improve patient outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/research-progress-of-nanodelivery-platforms-in-the-diagnosis-and-treatment-of-esophageal-cancer/359369/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/research-progress-of-nanodelivery-platforms-in-the-diagnosis-and-treatment-of-esophageal-cancer/359369.png","ImageObject",300,407,{"name":92,"@type":93},"Connor ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is esophageal cancer treatment challenging with current radiotherapy and chemotherapy?","Question",{"text":112,"@type":113},"Because toxicity limits their use, multidrug resistance develops over time, and immune responses are often insufficient for durable control.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does nanotechnology address these limitations in esophageal cancer therapy?",{"text":117,"@type":113},"It enables precise targeting and platform-based strategies that improve efficacy while reducing toxicity, including approaches to reverse drug resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"What roles do co-delivery strategies play in activating “cold tumors”?",{"text":121,"@type":113},"They empower photodynamic, gene, and immunotherapies together, reshaping the tumor microenvironment to promote immune activation in tumors with low baseline responsiveness.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},359369,1790194944,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},687207022233,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","International Journal of Nanomedicine  \nOpen Access Full Text Article REVIEW  \nResearch Progress of Nanodelivery Platforms in the Diagnosis and Treatment of Esophageal Cancer  \nShuaiqi Sun *, Haoyang Huang*, Haoxiang Hong *, Wenlong Lu*, Li Qiu, Shaowei Liu, Sihe Huang, Kaiwen Ye, Jian Sun, Gengliang Lai, Jun Liu  \nDepartment of Thoracic Surgery and Oncology, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, People’s Republic of China  \n*These authors contributed equally to this work  \nCorrespondence: Jun Liu, Department of Thoracic Surgery and Oncology, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, People’s Republic of China,  \nEmail [ljxwkgy@126.com](ljxwkgy@126.com)  \n\n| Abstract: Esophageal cancer treatment has long been limited by the toxicity of radiotherapy and chemotherapy, multidrug resistance, and low immune response. Nanotechnology, with its precise targeting advantages, offers a new solution. This article reviews its core advances: first, achieving enhanced efficacy and reduced toxicity of radiotherapy and chemotherapy, and reversing drug resistance; second, empowering photodynamic, gene, and immunotherapies, utilizing co-delivery strategies to reshape the microenvironment to activate “cold tumors”; and third, constructing a visualized integrated diagnostic and therapeutic platform. Although clinical translation still faces challenges related to biological barriers and mass production, the integration of biomimetic design, intelligent response, green manufacturing, and organoid screening technologies holds promise for bridging the translational gap and significantly improving patient prognosis.\u003Cbr>Keywords: nanodelivery system, multidrug resistance, immunotherapy, therapeutic integration, clinical translation |\n| --- |\n| Introduction\u003Cbr>Esophageal cancer (EC) is a highly aggressive malignant tumor with a very poor prognosis, with a five-year survival rate of only 10%–30% in most parts of the world. As the sixth leading cause of cancer death globally, EC places a heavy burden on public health, especially in high-incidence areas in East Asia such as China, where the five-year survival rate hovers below 30% .1\u003Cbr>EC is mainly divided into two subtypes: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) . The former is closely related to long-term physical and chemical irritants (such as smoking and alcohol consumption) and is dominant in developing countries; the latter is mostly caused by gastroesophageal reflux disease (GERD) and obesity and is more common in Western countries.2 Its risk factors include gastroesophageal reflux disease (GERD), obesity, and smoking. In addition, Barrett’s esophagus is its direct precancerous lesion.3 The treatment of EC is mainly based on the TNM stage and pathological type of the tumor.4 Surgery is the main treatment for early EC. For early lesions, the 5-year survival rate of surgical or endoscopic resection can be as high as 90% . However, for patients with more common locally advanced lesions, the effect of surgery alone is not ideal, and the recurrence rate after surgery is extremely high. Therefore, the current mainstream treatment model has shifted to “neoadjuvant therapy + surgery”, which can increase the 5-year survival rate to 40% – 50% . Nevertheless, the biggest bottleneck of surgical treatment is still the high recurrence rate, and about half of the patients still face the risk of tumor recurrence or metastasis after surgery. As a neoadjuvant therapy before surgery, radiotherapy and chemotherapy can effectively shrink the tumor and |\n\n[https://doi.org/10.2147/IJN.S588613](https://doi.org/10.2147/IJN.S588613)  \n[Received: 12 December 2025](Received: 12 December 2","cbCaici9OP4mBBXp","https://ap.wps.com/l/cbCaici9OP4mBBXp","pdf",4519602,"English","# Abstract\n# Introduction\n# Targeting and immunotherapy challenges\n# Nanodelivery platforms and integrated diagnosis-treatment","[{\"question\":\"Why is esophageal cancer treatment challenging with current radiotherapy and chemotherapy?\",\"answer\":\"Because toxicity limits their use, multidrug resistance develops over time, and immune responses are often insufficient for durable control.\"},{\"question\":\"How does nanotechnology address these limitations in esophageal cancer therapy?\",\"answer\":\"It enables precise targeting and platform-based strategies that improve efficacy while reducing toxicity, including approaches to reverse drug resistance.\"},{\"question\":\"What roles do co-delivery strategies play in activating “cold tumors”?\",\"answer\":\"They empower photodynamic, gene, and immunotherapies together, reshaping the tumor microenvironment to promote immune activation in tumors with low baseline responsiveness.\"}]","Research Progress of Nanodelivery Platforms in the Diagnosis and Treatment of Esophageal Cancer | PDF",1790136767,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d09a091734b411602e815b7e95bf5ed2.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97dd386fcac0023a4f354e4a6755ec9b.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/81beb4f87e28de3b6930da27784b320f.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/abae430bfb2530999a07241486fb7c10.webp",980,1268]